Literature DB >> 16900307

Aspirin resistance - does it clinically matter?

Karsten Schrör1, T Hohlfeld, A-A Weber.   

Abstract

A variable responsiveness to acetylsalicylic acid(ASA) is a clinical reality that does not principally differ from variable responses to other kinds of drug treatment in other therapeutic fields. Two questions arise: (i) is any resulting "treatment failure"due to a pharmacological failure of the drug to act and (ii) is any reduced antiplatelet activity to ASA related to the clinical outcome oft he patient?Two major laboratory techniques are available to quantify platelet variability to ASA ex vivo: Measurement of platelet function and measurement of thromboxane formation. Both methods have limitations and did not yet result in a generally accepted definition of a pharmacological ASA "resistance".A "true" pharmacological resistance to ASA exists in selected groups of patients. However, unless more information is available,results from in vitro assays of platelet function should not be over-interpreted. More data from prospective trials are required,predominantly by measuring serum thromboxane formation which is a platelet-specific, ASA sensitive reaction. At this time,there is no reason to change there commended daily maintenance dose of about 100 mg ASA without particular requirements in patients who need coronary protection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900307     DOI: 10.1007/s00392-006-0424-5

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  38 in total

Review 1.  Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance.

Authors:  Scott A McKee; David C Sane; Efthymios N Deliargyris
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

Review 2.  Scientific and therapeutic advances in antiplatelet therapy.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Nat Rev Drug Discov       Date:  2003-01       Impact factor: 84.694

3.  Aspirin resistance: a revival of platelet aggregation tests?

Authors:  G De Gaetano; C Cerletti
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

4.  Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.

Authors:  Pui-Yin Lee; Wai-Hong Chen; William Ng; Xi Cheng; Jeanette Yat-Yin Kwok; Hung-Fat Tse; Chu-Pak Lau
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

5.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.

Authors:  F Catella; D Healy; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 6.  Aspirin resistance and genetic polymorphisms.

Authors:  Josie A Cambria-Kiely; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

7.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

8.  Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.

Authors:  M R Buchanan; S J Brister
Journal:  Can J Cardiol       Date:  1995-03       Impact factor: 5.223

9.  The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.

Authors:  P R Mayeux; H E Morton; J Gillard; A Lord; T A Morinelli; A Boehm; D E Mais; P V Halushka
Journal:  Biochem Biophys Res Commun       Date:  1988-12-15       Impact factor: 3.575

10.  Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin.

Authors:  G Montalescot; J Maclouf; G Drobinski; J Salloum; Y Grosgogeat; D Thomas
Journal:  J Am Coll Cardiol       Date:  1994-07       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.